Gkv Capital Management Co., Inc. Arbutus Biopharma Corp Transaction History
Gkv Capital Management Co., Inc.
- $120 Billion
- Q1 2025
A detailed history of Gkv Capital Management Co., Inc. transactions in Arbutus Biopharma Corp stock. As of the latest transaction made, Gkv Capital Management Co., Inc. holds 6,300 shares of ABUS stock, worth $20,286. This represents 0.02% of its overall portfolio holdings.
Number of Shares
6,300Holding current value
$20,286% of portfolio
0.02%Shares
1 transactions
Others Institutions Holding ABUS
# of Institutions
190Shares Held
111MCall Options Held
866KPut Options Held
608K-
Morgan Stanley New York, NY23.8MShares$76.6 Million0.01% of portfolio
-
Whitefort Capital Management, LP New York, NY13.3MShares$42.9 Million27.3% of portfolio
-
Black Rock Inc. New York, NY11.6MShares$37.2 Million0.0% of portfolio
-
Two Seas Capital LP Rye, NY9.47MShares$30.5 Million1.19% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$28.8 Million0.0% of portfolio
About Arbutus Biopharma Corp
- Ticker ABUS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 149,951,008
- Market Cap $483M
- Description
- Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...